Form 4: Kraig Biocraft Laboratories CEO Acquires 62,500 Shares at $0.0906

Kimberly Kraig Thompson, CEO of Kraig Biocraft Laboratories, reports the acquisition of 62,500 shares of common stock at a price of $0.0906 per share on March 31, 2025.

Summary

• On March 31, 2025, Kimberly Kraig Thompson, the CEO of Kraig Biocraft Laboratories, acquired 62,500 shares of the company's common stock.
• The shares were purchased at a price of $0.0906 per share.
• Following this transaction, Thompson directly owns 201,650,422 shares of Kraig Biocraft Laboratories.
• The transaction was reported on April 08, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by the CEO. While insider buying can be seen as a positive signal, it's a single transaction and doesn't provide enough information to strongly indicate a positive or negative outlook.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency into the trading activities of key personnel.

Stakeholder Impact

• The CEO's stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Kraig Biocraft Laboratories, KBLB, Kimberly Kraig Thompson, CEO, stock acquisition, Form 4, beneficial ownership